Zai Lab Limited, a Shangai, China-based innovative biopharmaceutical company, raised US$30m in Series C equity financing.
The round was led by OrbiMed with participation from new investors Vivo Capital, Cormorant and Rock Springs Capital.
The company intends to use the proceeds to increase its research and development efforts and to support future partnering activities.
Zai Lab focuses on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical needs in the China market, including in the areas of oncology, autoimmune and infectious diseases. The company has assembled a pipeline of potential best-in-class and first-in-class in China therapeutics at different stages of development by securing partnerships with multinational pharmaceutical and innovative biotechnology companies.
FinSMEs
30/06/2017